Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: KVUE )

24.08 -0.01 (-0.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KVUE

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
2 Reasons to Buy Johnson & Johnson, and 1 Reason to Sell
This pharma company has reached an important transition point. 
Via The Motley Fool
3 Dividend Stocks to Buy Right This Minute
Boost your portfolio and generate passive income with these three dividend stocks to buy now and hold forever. 
Via InvestorPlace
If You Invested $5,000 In Johnson & Johnson In 2018, This Is How Much You Would Have Today
The longer you can stand to wait, the more this investment will pay off. 
Via The Motley Fool
7 Up-and-Coming Stocks to Buy for the Next Decade
While less-established enterprises are best left for speculators, these up-and-coming stocks to buy also feature huge upside potential. 
Via InvestorPlace
Moderating Inflation, a Tasty IPO, Bull Market Talk, and More
We've also got two stocks worth watching: Chevron and Burford Capital. 
Via The Motley Fool
Will Cava's Successful Debut Raise Hope For Reviving IPO Market?
Cava's strong IPO performance suggests a warming trend in the market for new public debuts. However, several eagerly anticipated offerings remain on hold. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts?
In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New York... 
Via Benzinga
3 Long-term Healthcare Stocks to Add to Your Portfolio
These long-term healthcare stocks should benefit from the global surge in spending for life-improving pharmaceutical drugs, therapies, and medical devices. 
Via InvestorPlace
Build a Millionaire’s Portfolio With These 3 Dividend-Paying Stocks
Use wealth-building dividend stocks to help build a portfolio that gets you closer to becoming a millionaire. 
Via InvestorPlace
7 Top Blue-Chip Stocks to Buy in June 2023
Investors who are looking to hold stocks through the summer should be looking for the best blue-chip stocks to buy. 
Via InvestorPlace
The 3 Best Long-Term Dividend Stocks to Buy in June
Build a solid investment portfolio with the best long-term dividend stocks and enjoy passive income for many years to come. 
Via InvestorPlace
Kenvue to Announce Second Quarter 2023 Results on July 20, 2023
From Kenvue Inc.
Via Business Wire
1 Ultra-Elite Dividend Stock to Buy Hand Over Fist in June
The company offers a super-safe dividend with a compelling upside catalyst. 
Via The Motley Fool
3 Warren Buffett Stocks to Buy (and Never Sell)
Investors who are looking for safe retirement stocks often turn to Warren Buffett's portfolio to get a sense of which stocks to buy. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
Kenvue to Participate in the Deutsche Bank dbAccess Global Consumer Conference on June 8, 2023
From Kenvue Inc.
Via Business Wire
Kenvue's Growth Forecast: Exploring The Future Of Johnson & Johnson's Carve-Out
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
Via Benzinga
7 Consumer Stocks to Buy and Hold for the Long Haul
For steady dividends and price appreciation, consider adding these seven best long-term consumer stocks to your portfolio. 
Via InvestorPlace
3 Dow Stocks Poised for a Roaring Relief Rally
Here are some compelling Dow stocks to buy if you believe the market may be on the cusp of a relief rally this summer. 
Via InvestorPlace
Got $1,000? 5 Buffett Stocks to Buy and Hold Forever
Warren Buffett owns many stocks, but these five have solid growth potential. 
Via The Motley Fool
Kenvue Just IPO'd, but Is the Stock a Buy?
The Johnson & Johnson spinoff is worth considering, but it's not a must-buy. 
Via The Motley Fool
2 Dividend Stocks to Double Up On Right Now
These dividend stocks look attractive right now. 
Via The Motley Fool
Kenvue Has Gone Public: Should You Buy the Stock?
Its business could be resistant to the effects of inflation. 
Via The Motley Fool
Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?
Both stocks have built-in economic diversity and are solid long-term investments. 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
Boring businesses can make for beautiful lifelong holdings -- these two stocks show us why. 
Via The Motley Fool
How Apple Pleased Investors
We've got a lot of ground to cover as company earnings reports continue to flood in. 
Via The Motley Fool
7 Overvalued Stocks to Sell for May 2023
It's easy to fall into the trap of getting overvalued stocks. What may have been a great buy a year ago could be overvalued today. 
Via InvestorPlace
2 Warren Buffett Stocks to Buy Hand Over Fist in May
These two Berkshire Hathaway holdings are solid picks in May. 
Via The Motley Fool
J&J Kenvue Spinoff Aims To Give Investors A Healthy Return
Johnson & Johnson spinoff Kenvue had the biggest IPO since 2021, raising $3.8 billion. Kenvue's brands include Band-Aid, Tylenol, Neutrogena and Listerine. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.